The company, founded in 2004 as a spin-off of Shinshu University, has developed an i-DPS technology” for cancer immunotherapy and severe lower limb ischemia. I-DPS utilizes the anaerobic nature of Bifidobacteria to produce pharmacologically active substances where Bifidobacteria selectively accumulate in lesions of hypoxic environment such as solid cancers. Bifidobacteria do not accumulate in normal aerobic tissues and do not produce toxins. APS001F, the most advanced candidate, is designed to express cytosine deaminase (CD) enzyme after reaching solid cancer by intravenous administration. The new investment comes from a Novartis-operated fund.”

Aneropharma Science news release, July 5, 2017